Predicting time to treatment in follicular lymphoma on watchful waiting using baseline metabolic tumour burden.
FDG
Follicular lymphoma
Metabolic tumour volume
PET
PET/CT
Watchful waiting
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
31
03
2022
accepted:
13
06
2022
medline:
5
7
2023
pubmed:
3
7
2022
entrez:
2
7
2022
Statut:
ppublish
Résumé
Asymptomatic patients with follicular lymphoma (FL) and a low tumour burden can be followed without initial therapy, a strategy called watchful waiting (WW). Prediction of the time to treatment (TTT) is still a challenge. We investigated the prognostic value of baseline total metabolic tumour volume (TMTV) and whole-body total lesion glycolysis (WB-TLG) to predict TTT in patients with FL on WW. We conducted a retrospective study of 54 patients with FL (grade 1-3a) diagnosed between June 2013 and December 2019, staged with FDG PET/CT, and managed on WW. Median age was 62 years (range 34-85), stage was advanced (III-IV) in 57%, and FLIPI score was intermediate to high (≥ 2) in 52% of the patients. The median TMTV and WB-TLG were 7.1 and 43.3, respectively. With a median follow-up of 59 months, 41% of patients started immuno-chemotherapy. The optimal cut-points to identify patients with TTT within 24 months were 14 for TMTV (AUC 0.70; 95% CI 51-88) and 64 for WB-TLG (AUC 0.71; 95% CI 52-89) (p < 0.005). The probability of not having started treatment within 24 months was 87% for TMTV < 14 and 53% for TMTV ≥ 14 (p < 0.005). TMTV was independent of the FLIPI score for TTT prediction. Patients with both FLIPI ≥ 2 and TMTV ≥ 14 had only an 18% probability of not having started treatment at 36 months, while this probability was 75% in patients with TMTV < 14. Metabolic tumour volume parameters may add information to clinical scores to better predict TTT and better stratify patients for interventional studies.
Identifiants
pubmed: 35779106
doi: 10.1007/s00432-022-04138-3
pii: 10.1007/s00432-022-04138-3
pmc: PMC10314847
doi:
Substances chimiques
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2783-2791Informations de copyright
© 2022. The Author(s).
Références
J Clin Oncol. 1997 Mar;15(3):1110-7
pubmed: 9060552
Clin Cancer Res. 2016 Aug 1;22(15):3801-9
pubmed: 26936916
Pathologica. 2010 Jun;102(3):83-7
pubmed: 21171509
J Clin Oncol. 2014 Sep 20;32(27):3059-68
pubmed: 25113753
Blood. 2004 Sep 1;104(5):1258-65
pubmed: 15126323
Br J Radiol. 2021 Nov 1;94(1127):20210448
pubmed: 34379496
Mol Imaging Biol. 2020 Aug;22(4):1102-1110
pubmed: 31993925
Am J Hematol. 2015 Dec;90(12):1171-8
pubmed: 26769125
J Clin Oncol. 2014 Sep 20;32(27):3048-58
pubmed: 25113771
Clin Lymphoma Myeloma Leuk. 2020 Jan;20(1):39-46
pubmed: 31761712
Cancer Manag Res. 2019 Jul 23;11:6871-6885
pubmed: 31413633
Nucl Med Mol Imaging. 2018 Feb;52(1):5-15
pubmed: 29391907
Blood. 2018 May 31;131(22):2449-2453
pubmed: 29559480
J Clin Oncol. 2012 Nov 1;30(31):3848-53
pubmed: 23008294
J Clin Oncol. 2016 Oct 20;34(30):3618-3626
pubmed: 27551111
Eur J Nucl Med Mol Imaging. 2019 Feb;46(2):520-521
pubmed: 30386867
Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):328-54
pubmed: 25452219
Br J Haematol. 2020 Jun;189(6):1083-1092
pubmed: 32065396
Blood Adv. 2021 Mar 9;5(5):1283-1290
pubmed: 33651099
J Clin Oncol. 2009 Sep 20;27(27):4555-62
pubmed: 19652063
J Nucl Med. 2017 Feb;58(2):276-281
pubmed: 27754905
J Clin Oncol. 2013 Sep 10;31(26):3272-8
pubmed: 23897955
Int J Radiat Oncol Biol Phys. 2012 Mar 1;82(3):1164-71
pubmed: 21531085
Am J Nucl Med Mol Imaging. 2013 Apr 09;3(3):272-81
pubmed: 23638338
Clin Cancer Res. 2016 Jul 1;22(13):3414-5
pubmed: 27371634
Eur J Nucl Med Mol Imaging. 2014 Jun;41(6):1113-22
pubmed: 24570094
Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2017-22
pubmed: 24902639